High Tide (HITI) Q4 2025 earnings review
Revenue Accelerates, But One-Time Charges Muddle Profit Picture
High Tide ended fiscal 2025 on a high note operationally, posting record revenue of $164M (+19% YoY) and record Adjusted EBITDA of $12.4M (+51% YoY). Revenue growth accelerated for the third consecutive quarter, driven by strong same-store sales (+5.5%) and rapid growth in its Cabana Club loyalty program. However, the strong operating results were overshadowed by a massive $46.7M GAAP net loss due to non-cash impairment and derivative charges. Furthermore, quarterly Free Cash Flow fell sharply to $1.3M, a 78% YoY decline, raising questions about working capital needs for its new German venture.
🐂 Bull Case
YoY revenue growth accelerated to 19%, the fastest rate in nine quarters. Adjusted EBITDA grew 51% YoY as margins expanded for the fourth straight quarter, demonstrating strong operating leverage.
The Canadian Cabana Club loyalty program grew 45% YoY to 2.5 million members, while the paid ELITE tier more than doubled to 151,000 members. This ecosystem drives higher sales and market share.
🐻 Bear Case
A reported net loss of $46.7M, driven by over $47M in non-cash impairment and derivative liability charges, clouds the quality of earnings and raises questions about asset valuation and financial complexity.
Quarterly Free Cash Flow dropped to just $1.3M from $7.7M in Q3 and $5.9M a year ago. While the company met its full-year positive FCF goal, the sharp decline warrants scrutiny.
⚖️ Verdict: ⚪
Neutral. The accelerating top-line growth and improving operational profitability are impressive and show the core retail strategy is working. However, the jarring GAAP loss and a sudden, sharp drop in free cash flow are significant red flags that temper the positive operational story.
Key Themes
Profitability and Operating Leverage Improving
High Tide demonstrated impressive margin expansion, with Adjusted EBITDA margin increasing every quarter in fiscal 2025, ending at 7.6% in Q4 from 5.0% in Q1. This was driven by operating leverage, as Salaries, Wages, and Benefits as a percentage of revenue fell to 11.5%, its lowest level in over two years. This shows the company's discount club model can scale efficiently.
Free Cash Flow Plummets in Q4
Free Cash Flow has been a key part of High Tide's investment case, but it fell to just $1.3M in Q4, down from $7.7M in Q3 and reversing a trend of strong cash generation. Management attributed the drop to a $2.3M working capital investment. While the company met its goal of being FCF positive for the full year ($12.0M), this sudden deceleration raises concerns about the cash requirements needed to fund its new German operations and domestic store growth.
E-Commerce Segment Remains a Drag
The company's e-commerce division continues to shrink, now accounting for only 2% of consolidated revenue. In Q3, the last period with a segment breakdown, it generated an operating loss of nearly $2.9M. While High Tide is exploring a potential opportunity related to a new US Medicare pilot program for CBD products, the segment has been a consistent underperformer and a drag on overall profitability.
Loyalty Program Drives Market Share Gains
High Tide's Cabana Club remains its primary competitive advantage. Canadian membership grew 45% YoY to 2.5 million, while the paid ELITE membership tier grew an explosive 107% YoY to 151,000. This powerful ecosystem drives repeat business and network effects, helping High Tide grow its market share to 12% across its five operating provinces, up from 11% a year ago.
German Expansion Provides New Growth Vector
The acquisition of a majority stake in Remexian Pharma marks High Tide's strategic entry into Germany, Europe's largest medical cannabis market. Despite a temporary supply chain disruption, management noted that momentum is returning, with December representing the second-highest sales month ever for Remexian. This move diversifies the company's revenue base away from Canadian retail.
GAAP Profitability Obscured by Large Non-Cash Charges
While management highlighted record Adjusted EBITDA, the GAAP net loss of $46.7M cannot be ignored. The loss was almost entirely due to two non-cash items: a $23.6M impairment charge and a $23.5M loss on the fair value of derivative liabilities. This contradicts the positive operational narrative. While not a cash expense, these charges point to potential overvaluation of assets from prior acquisitions and add significant complexity to the financial statements.
Other KPIs
Consolidated gross margin was stable YoY but declined sequentially from 27% in Q3. Management attributed this to liquidating lower-margin, expiring biomass at its newly acquired German subsidiary, Remexian. Importantly, the company stated that margins in its core Canadian bricks-and-mortar segment, which represents 92% of revenue, increased for the fourth consecutive quarter.
Same-store sales growth remains robust, indicating healthy demand at existing locations and the success of the company's discount club model. This marks the 15th consecutive quarter of positive same-store sales growth, a strong indicator of the Canna Cabana brand's resonance with consumers.
The company ended the year with a healthy cash balance. However, this was down from $63.8M at the end of Q3. The decline reflects $12.3M in cash paid for the Remexian acquisition and other operational uses. The cash position remains solid, providing flexibility for the planned 20-30 new store openings in 2026.
Guidance
Stable. The company plans to continue its measured retail expansion, targeting a similar number of openings as the 27 completed in calendar 2025. Growth will be primarily organic, with management also evaluating M&A.
The company expects to remain free cash flow positive for the full fiscal year 2026. This is a critical commitment for investors, especially following the weak FCF result in Q4 2025. Achieving this will depend on managing the working capital needs of the growing German business.
This remains a long-term goal for margin enhancement. Currently, white label products represent only 1% of cannabis sales, indicating a very long runway but also significant execution risk to achieve this ambitious target.
Key Questions
Bridging the Free Cash Flow Decline
Can you provide more detail on the $2.3M working capital investment in Q4? As the German Remexian business scales in 2026, what level of ongoing working capital investment should we expect, and how does that factor into your confidence in remaining free cash flow positive for the year?
Impairment and Derivative Charges
Could you offer more specifics on the assets that were impaired for $23.6M and the primary drivers behind the $23.5M fair value loss on derivative liabilities? Are further similar charges anticipated in the near future?
E-Commerce Strategy and Hurdles
With the e-commerce segment now just 2% of sales, can you quantify the resources (capital and personnel) dedicated to it? What specific milestones are you looking for from the potential US Medicare CBD pilot to justify continuing to hold these assets versus divesting?
Consolidated Gross Margin Outlook
You noted that the core Canadian retail margin improved, but the consolidated margin was impacted by the new German business. As Remexian's sales grow, where do you expect consolidated gross margins to trend in fiscal 2026?